Please login to the form below

Not currently logged in


This page shows the latest Enhertu news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to treat unresectable or metastatic HER2-low breast cancer. ... In addition to its indications in breast cancer, Enhertu has also

Latest news

More from news
Approximately 12 fully matching, plus 12 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

The challenges of identifying rare diseases
With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...